For Employers

Omada Health Reports Second Quarter 2025 Results

Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025.

Read Article

22 days ago

Patients, providers and payers alike are investing in GLP-1 medications - but are they seeing the value they expected?

In this ~2-minute video, Omada's Senior Director of Clinical and Translational Research, Sarah Linke, summarizes findings of our July 2025 clinical white paper on GLP-1 Persistence

Read Article

26 days ago

Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results.

Read Article

Error - something went wrong!

Become an Omada Insider, subscribe to our monthly newsletter

Thank you!

about 2 months ago

Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises

Read Article

about 2 months ago

GLP-1 Medication Persistence, a Key Component of Weight Loss

Medication persistence, or remaining on a medication as prescribed, is crucial for meaningful obesity management outcomes.

Read Resource

2 months ago

Omada Health Announces Pricing of Initial Public Offering

Omada Health, the virtual between-visit healthcare provider, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock, at a public offering price of $19.00 pe

Read Article

3 months ago

Omada Health Announces Launch of Initial Public Offering

Omada Health announces its initial public offering, offering 7.9 million shares at $18–$20 each, and plans to list on Nasdaq under the ticker symbol “OMDA.”

Read Article

3 months ago

Omada Horizon Day - The Food Experience 2025

On May 20, 2025, Omada Horizon Day showcased how our AI-powered innovations are transforming member relationships with food. Watch the recording of our Spring 2025 product innovation unveiling!

Watch Video

3 months ago

3 Reasons Behavior Change Support is Vital to Obesity Care

Why GLP-1s are not a silver bullet for obesity, the role of behavior change support teams and how they complement obesity medicine specialists, and how providers can achieve optimal outcomes.

Read Article

3 months ago

5 Key Lessons Learned in the U.S. about Weight Loss Drugs

This edition covers the imminent expansion of GLP-1s on a worldwide scale, the global burden and prevalence of obesity and chronic diseases, and the clinical and economic realities of GLP-1 expansion.

Read Article

3 months ago

Building Self Efficacy in the Era of GLP-1s

Self-efficacy is key for long-term GLP-1 weight loss success. Find out how Omada’s Enhanced GLP-1 Care Track helps members achieve sustainable weight health.

Read Article

3 months ago

Lower Acute Healthcare Utilization Associated with Virtual Cardiometabolic Health Programs

This analysis found that lifestyle-focused virtual health program to support cardiometabolic disease management may lead to meaningful reductions in high-cost acute care encounters.

Read Article

Become an Omada Insider, subscribe to our monthly newsletter

Sign Me Up

3 months ago

Life After GLP-1s: A Real-World Population Snapshot

This analysis evaluated demographic & clinical characteristics of adults without diabetes who reported recent use of GLP-1s for weight loss while enrolled in a digital weight management program.

Read Article

4 months ago

New Indications, Promising Outcomes, and Third-Party Prescribing

As the GLP-1 conversation evolves, Omada Health is updating its industry FAQs to deliver timely data and insights for virtual care buyers.

Read Article

4 months ago

Why Honesty is the Best Policy as AI Continues Shaping Healthcare: Q&A with Lucia Savage, Chief Privacy & Regulatory Officer

Should you trust healthcare AI? Learn about safe development and deployment practices, and the future of AI regulation in healthcare.

Read Article

4 months ago

New Data Demonstrates Behavioral, Mental, and Physical Health Benefits of Omada Health’s Cardiometabolic Programs

Omada Health presented three posters at the Society of Behavioral Medicine's Annual Meeting. New data demonstrates behavioral, mental, and physical health benefits of Omada's cardiometabolic programs.

Read Article

5 months ago

Early Insights from a GLP-1 Focused Care Track within a Virtual Health Program

This analysis found that providing Omada members the opportunity to make a guided decision about curriculum theme resulted in greater engagement compared to receiving content in a standardized order.

Read Article

5 months ago

Omada Health Enhances Clinical Advisory Board to Further Advance Clinical Excellence

Omada’s Clinical Advisory Board demonstrates its commitment to rigorous clinical evaluation and helps underscore the impact of its behavior change programs

Read Article

5 months ago

Improvement in depression and anxiety symptoms among participants in a virtual cardiometabolic condition management program

This analysis showed that across diverse sociodemographic populations, Omada cardiometabolic members experienced improvements in depression and anxiety symptoms.

Read Article

5 months ago

The Impact of Providing Guided Choice in a Virtual Prevention Program

This analysis found that providing Omada members the opportunity to make a guided decision about curriculum theme resulted in greater engagement compared to receiving content in a standardized order

Read Article

The Omada Platform

PROGRAMS

Insights Lab

WHO WE SERVE

About Omada

Omada For Employers

For Employers

Omada Health Reports Second Quarter 2025 Results

Patients, providers and payers alike are investing in GLP-1 medications - but are they seeing the value they expected?

Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

GLP-1 Medication Persistence, a Key Component of Weight Loss

Omada Health Announces Pricing of Initial Public Offering

Omada Health Announces Launch of Initial Public Offering

Omada Horizon Day - The Food Experience 2025

3 Reasons Behavior Change Support is Vital to Obesity Care

5 Key Lessons Learned in the U.S. about Weight Loss Drugs

Building Self Efficacy in the Era of GLP-1s

Lower Acute Healthcare Utilization Associated with Virtual Cardiometabolic Health Programs

Life After GLP-1s: A Real-World Population Snapshot

New Indications, Promising Outcomes, and Third-Party Prescribing

Why Honesty is the Best Policy as AI Continues Shaping Healthcare: Q&A with Lucia Savage, Chief Privacy & Regulatory Officer

New Data Demonstrates Behavioral, Mental, and Physical Health Benefits of Omada Health’s Cardiometabolic Programs

Early Insights from a GLP-1 Focused Care Track within a Virtual Health Program

Omada Health Enhances Clinical Advisory Board to Further Advance Clinical Excellence

Improvement in depression and anxiety symptoms among participants in a virtual cardiometabolic condition management program

The Impact of Providing Guided Choice in a Virtual Prevention Program

Become an Omada Insider